AU2014361788B2 - Multi-epitope TARP peptide vaccine and uses thereof - Google Patents

Multi-epitope TARP peptide vaccine and uses thereof Download PDF

Info

Publication number
AU2014361788B2
AU2014361788B2 AU2014361788A AU2014361788A AU2014361788B2 AU 2014361788 B2 AU2014361788 B2 AU 2014361788B2 AU 2014361788 A AU2014361788 A AU 2014361788A AU 2014361788 A AU2014361788 A AU 2014361788A AU 2014361788 B2 AU2014361788 B2 AU 2014361788B2
Authority
AU
Australia
Prior art keywords
tarp
peptide
peptides
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014361788A
Other languages
English (en)
Other versions
AU2014361788A1 (en
Inventor
Jay A. Berzofsky
Brenda D. Roberson
Masaki R. Terabe
Lauren V. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of AU2014361788A1 publication Critical patent/AU2014361788A1/en
Application granted granted Critical
Publication of AU2014361788B2 publication Critical patent/AU2014361788B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014361788A 2013-12-13 2014-12-12 Multi-epitope TARP peptide vaccine and uses thereof Active AU2014361788B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915948P 2013-12-13 2013-12-13
US61/915,948 2013-12-13
PCT/US2014/070144 WO2015089469A1 (en) 2013-12-13 2014-12-12 Multi-epitope tarp peptide vaccine and uses thereof

Publications (2)

Publication Number Publication Date
AU2014361788A1 AU2014361788A1 (en) 2016-06-30
AU2014361788B2 true AU2014361788B2 (en) 2019-10-10

Family

ID=52432905

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014361788A Active AU2014361788B2 (en) 2013-12-13 2014-12-12 Multi-epitope TARP peptide vaccine and uses thereof

Country Status (7)

Country Link
US (1) US10286050B2 (OSRAM)
EP (1) EP3079716B1 (OSRAM)
JP (1) JP6758185B2 (OSRAM)
AU (1) AU2014361788B2 (OSRAM)
CA (1) CA2932248C (OSRAM)
DK (1) DK3079716T3 (OSRAM)
WO (1) WO2015089469A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016343845B2 (en) 2015-10-30 2023-04-13 Baylor College Of Medicine Compositions and methods for the treatment of HER2-expressing solid tumors
WO2024086169A2 (en) * 2022-10-17 2024-04-25 Pds Biotechnology Corporation Novel non-hla restricted t cell vaccine for tcr gamma alternate reading frame protein (tarp) protein expressing cancers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000889A1 (en) * 2003-06-05 2005-01-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides for the treatment of prostate and breast cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
BR9206310A (pt) 1991-07-25 1995-04-25 Idec Pharma Corp Indução de respostas citotóxicas de linfócitos T.
US5709860A (en) 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
DE69332485T2 (de) 1992-08-11 2003-11-13 The President And Fellows Of Harvard College, Cambridge Immunmodulierende peptide
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
JP3468773B2 (ja) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
CN1378594A (zh) 1999-07-13 2002-11-06 美国政府健康及人类服务部 T－细胞受体r可变阅读框架蛋白(TARP)及其应用
SE9903031D0 (sv) * 1999-08-27 1999-08-27 Eurodiagnostica Ab Peptide mixture and vaccine against a chronic viral infection
AU2003245729A1 (en) * 2002-06-27 2004-01-19 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
KR20090024292A (ko) 2006-06-28 2009-03-06 스태튼스 세룸 인스티튜트 단백질 단편 또는 펩타이드 혼합물로서 전달되는 항원을 가진 백신접종에 의해 준우성 항원결정기를 포함하는 ｔ세포 레퍼토리 확장

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000889A1 (en) * 2003-06-05 2005-01-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides for the treatment of prostate and breast cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MIRSHAHIDI S ET AL, "Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: Prolonged survival", VACCINE, vol. 27, no. 12, doi:10.1016/J.VACCINE.2009.01.089, (2009-03-13), pages 1825 - 1833, (2009-02-06) *

Also Published As

Publication number Publication date
US10286050B2 (en) 2019-05-14
JP2017500305A (ja) 2017-01-05
AU2014361788A1 (en) 2016-06-30
DK3079716T3 (da) 2019-08-19
JP6758185B2 (ja) 2020-09-23
CA2932248A1 (en) 2015-06-18
EP3079716A1 (en) 2016-10-19
CA2932248C (en) 2022-08-02
EP3079716B1 (en) 2019-05-08
US20160310585A1 (en) 2016-10-27
WO2015089469A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
US20230414735A1 (en) Neoantigens and methods of their use
US11298398B2 (en) Method of treating a philadelphia chromosome-positive tumor
KR102874251B1 (ko) 신생항원 및 이의 용도
JP2024045573A (ja) 腫瘍特異的なネオ抗原を同定する組成物および方法
JP6444336B2 (ja) ポリペプチド
US9907842B2 (en) Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of cancer
US8043623B2 (en) Immunogenic peptides for the treatment of prostate and breast cancer
US9937250B2 (en) Immunogenic tumor associated stromal cell antigen peptides and methods of their use
AU2014361788B2 (en) Multi-epitope TARP peptide vaccine and uses thereof
US8378071B2 (en) Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
US9394352B2 (en) Immunogenic POTE peptides and methods of use
RU2773273C2 (ru) Неоантигены и способы их использования

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)